Vigabatrin Ph 1 Cocaine Interaction Study

Status Completed

Clinical Trial Summary

This is a Phase 1 safety/tolerably study to determine if there are clinically significant interactions between oral vigabatrin (gamma vinyl-gamma-amino butyric acid; VGB) concurrent with intravenous (IV) cocaine infusions.

Clinical Trial Description

STUDY DESIGN: This is a randomized, double-blind, placebo-controlled, parallel group study of the effects of VGB compared to placebo control on the physiological and subjective effects of IV infusions of cocaine (cocaine experienced volunteers).

Subjects will be randomized within each clinical site to one of four groups (placebo control or one of three doses of VGB twice daily).During VGB steady state dosing, subjects will receive double-blind infusions of saline and cocaine. Subjects will be asked to return for follow-up approximately 7 and 14 days after the day of clinic discharge.

STUDY DURATION: The maximum duration is 56 days, including 14 inpatient days of assessments and investigational products administration, and two follow-up visits after clinic discharge.

SAMPLE SIZE: Twenty-four subjects will be randomized to one of three doses of vigabatrin or placebo.

POPULATION: Volunteer, cocaine-experienced, non-treatment seeking cocaine users, 18 to 45 years of age. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00626834
Study type	Interventional
Source	National Institute on Drug Abuse (NIDA)
Contact
Status	Completed
Phase	Phase 1
Start date	February 2008
Completion date	October 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04336293` - sTMS for Substance Use-disordered Veterans	N/A
Completed	`NCT02939352` - The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues	Early Phase 1
Completed	`NCT01822587` - Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving	Phase 2
Completed	`NCT01601743` - Exercise as a Behavioral Treatment for Cocaine Dependence	N/A
Completed	`NCT02563769` - Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study	Phase 1
Completed	`NCT01651377` - Pramipexole as a Treatment for Cocaine Dependence	Phase 1
Completed	`NCT02768441` - Dexamphetamine Sustained Release Pharmacokinetics and Clinical Validation of Dried Blood Spots	Early Phase 1
Completed	`NCT02626494` - Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction	Phase 4
Recruiting	`NCT02892851` - Deep Brain Stimulation of the Sub-Thalamic Nucleus to Treat Severe and Treatment-resistant Cocaine Addiction.	N/A
Not yet recruiting	`NCT01319214` - Reducing Drug Craving Memories	N/A
Recruiting	`NCT01259362` - Effects of Repeated Transcranial Magnetic Stimulation (rTMS) on the Treatment of Cocaine Addicted Patients	Phase 2
Completed	`NCT01211418` - Integrative Meditation (IM) for Cocaine Addiction	N/A
Recruiting	`NCT03423667` - Efficacy of N-acetylcysteine on the Craving Symptoms of Abstinent Hospitalized Patients With Cocaine Addiction	Phase 2
Completed	`NCT01887366` - Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects	Phase 2
Completed	`NCT01984177` - Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence	N/A
Completed	`NCT01337297` - Prefrontal Cortex Stimulation as Treatment for Crack-cocaine Addiction	Phase 1/Phase 2
Completed	`NCT01067846` - Cognitive Enhancement and Relapse Prevention in Cocaine Addiction	N/A
Completed	`NCT01651364` - A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence	Phase 1
Recruiting	`NCT03018236` - Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.	Phase 4
Completed	`NCT01929343` - Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving	Phase 2